Latest Commercial Modelling News

Synertec’s Powerhouse platform has been selected by Amplitude Energy to optimise power at the Orbost Gas Processing Plant, marking a strategic step into large-scale industrial energy solutions.

Cyclopharm Limited delivered a record $17.1 million in revenue for 1H FY26, driven by a 73% surge in US Technegas® sales. However, delays in clinical guideline publication have pushed the short-term US installation target beyond 2026, while medium-term ambitions remain intact.

Talius has landed a $1.15 million contract with Seventh-day Adventist Aged Care (North NSW), doubling its recent Queensland deal and adding over $100,000 in annual recurring revenue.

Livium is positioning its Envirostream subsidiary to capitalise on the growing battery recycling needs from Australia's booming AI data centre sector, leveraging its EPA-licensed facilities and national network.

Mount Hope Mining (ASX:MHM) has completed two drilling phases at its Mt Solitary gold project in NSW’s Cobar Basin, delivering significant high-grade gold intercepts and preparing to launch an expanded Phase 3 drilling campaign targeting resource growth.

Memphasys has inked its first exclusive commercialization agreement in South-East Asia with TMSC Vietnam, targeting the fast-growing Vietnamese IVF sector with its Felix™ sperm separation system. The two-year contract, valued at A$530,000, hinges on regulatory approval expected by August 2026.

Provaris Energy's proprietary liquified CO2 tank design has cleared a crucial Concept Selection milestone with Yinson, broadening its application beyond floating storage units to carriers and terminals, and advancing its path towards commercialisation.

Gold Hydrogen is accelerating Helium development at its Ramsay Project, leveraging exceptional purity results and independent modelling amid a tightening global Helium supply.

Xenitra Limited's OPAL Real World Asset tokenised sales ecosystem has generated over $500,000 in sales within its first month, onboarding more than 130 distributors and positioning the company as an early mover in blockchain-enabled FMCG sales in China.

dorsaVi has initiated its Ultra-Edge Modular Design program, transitioning from IP development to a manufacturable hardware platform targeting robotics, exoskeletons, and industrial AI with ultra-low power consumption.

Entropy Neurodynamics has unveiled a striking 75% response rate in a small Phase 2a trial of its oral psilocybin therapy for treatment-resistant irritable bowel syndrome, far surpassing existing treatments and validating its gut-brain axis approach.

EVE Health Group has begun commercial sales of Libbo, an oral dissolving film for erectile dysfunction, supported by a new digital men’s health platform. The company also expanded its pharmaceutical pipeline and secured $1.3 million in fresh capital to fund ongoing development and commercialization.